AU2020269379A1 - Compositions comprising indigo and/or an indigo derivative and methods of use thereof - Google Patents

Compositions comprising indigo and/or an indigo derivative and methods of use thereof Download PDF

Info

Publication number
AU2020269379A1
AU2020269379A1 AU2020269379A AU2020269379A AU2020269379A1 AU 2020269379 A1 AU2020269379 A1 AU 2020269379A1 AU 2020269379 A AU2020269379 A AU 2020269379A AU 2020269379 A AU2020269379 A AU 2020269379A AU 2020269379 A1 AU2020269379 A1 AU 2020269379A1
Authority
AU
Australia
Prior art keywords
indirubin
dosage form
indigo
dispersion
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020269379A
Other languages
English (en)
Inventor
Johan ANDREASSON
Matthew Davidson
Michael David FAVERO
Matthew Benjamin Greene
Julie SAIKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azora Therapeutics Inc
Original Assignee
Azora Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azora Therapeutics Inc filed Critical Azora Therapeutics Inc
Publication of AU2020269379A1 publication Critical patent/AU2020269379A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020269379A 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof Abandoned AU2020269379A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843184P 2019-05-03 2019-05-03
US62/843,184 2019-05-03
PCT/US2020/031174 WO2020227151A1 (en) 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2020269379A1 true AU2020269379A1 (en) 2021-12-02

Family

ID=70775588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020269379A Abandoned AU2020269379A1 (en) 2019-05-03 2020-05-01 Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Country Status (10)

Country Link
US (3) US20200345645A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962458A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022531012A (cg-RX-API-DMAC7.html)
KR (1) KR20220044435A (cg-RX-API-DMAC7.html)
CN (1) CN114340600A (cg-RX-API-DMAC7.html)
AU (1) AU2020269379A1 (cg-RX-API-DMAC7.html)
CA (1) CA3136081A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021013386A (cg-RX-API-DMAC7.html)
TW (1) TW202106296A (cg-RX-API-DMAC7.html)
WO (1) WO2020227151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
TWI836752B (zh) 2021-11-30 2024-03-21 美商安督奎斯特機器人公司 用於機器人控制醫療裝置的力傳輸系統
WO2023170714A1 (en) * 2022-03-10 2023-09-14 Joy Vadakkan Thomas A topical herbal composition for fungal infection, scaling, foot cracking, eczema and dry skin diseases
KR20250069676A (ko) * 2022-10-10 2025-05-19 더데르마 상하이 컴퍼니 리미티드 궤양 예방 및/또는 치료를 위한 스틸벤 유도체의 용도
WO2025008784A1 (en) * 2023-07-04 2025-01-09 Glenmark Life Sciences Limited Solid dispersions of tapinarof and a process for the preparation thereof
CN121337758A (zh) * 2025-11-26 2026-01-16 河北省中医院(河北中医药大学第一附属医院、河北省青少年儿童脊柱侧弯防控中心) 一种可降解的肠道药物靶向释放胶囊及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
JP6382187B2 (ja) * 2012-06-21 2018-08-29 フォスフォレックス,インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
JP2017500343A (ja) * 2013-12-20 2017-01-05 フォスフォレックス,インコーポレーテッド インジルビン固体分散体組成物
TWI737602B (zh) 2015-04-09 2021-09-01 瑞士商高德美公司 藥學組合物及其製劑
CA3021071A1 (en) * 2016-04-19 2017-10-26 Ferring B.V. Oral pharmaceutical compositions of mesalazine
WO2019142799A1 (ja) * 2018-01-18 2019-07-25 学校法人慶應義塾 潰瘍性大腸炎治療カプセル剤

Also Published As

Publication number Publication date
KR20220044435A (ko) 2022-04-08
JP2022531012A (ja) 2022-07-05
US20250255820A1 (en) 2025-08-14
MX2021013386A (es) 2022-03-22
TW202106296A (zh) 2021-02-16
CN114340600A (zh) 2022-04-12
EP3962458A1 (en) 2022-03-09
WO2020227151A1 (en) 2020-11-12
US20220249382A1 (en) 2022-08-11
US20200345645A1 (en) 2020-11-05
CA3136081A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
US20250255820A1 (en) Compositions comprising indigo and/or an indigo derivative and methods of use thereof
US11173123B2 (en) Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US5415871A (en) Therapeutic agents
US20130259906A1 (en) Pharmaceutical composition comprising one or more fumaric acid esters
EP3923914B1 (en) Afabicin formulation, method for making the same
JP2008163038A (ja) 経口抗菌医薬組成物
GB2414668A (en) Sustained release delivery system for tetracycline compounds
US20200345691A1 (en) Compositions comprising indigo and/or an indigo derivative and methods of use thereof
WO2022157357A1 (en) Prolonged-release furazidin composition
HK40063531A (en) Afabicin formulation, method for making the same
HK40063531B (en) Afabicin formulation, method for making the same
AU2010211985A1 (en) Chronotherapeutic pharmaceutical composition
Asif Design and Characterization of Colon Targeted Nimesulide Double Coated Tablets for the Prophylaxis of Colon Cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period